

Holger Gothe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7384313/publications.pdf>

Version: 2024-02-01

48
papers

2,276
citations

394421

19
h-index

223800

46
g-index

70
all docs

70
docs citations

70
times ranked

2788
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. The Cochrane Library, 2010, , CD006632.	2.8	451
2	Economic burden of stroke: a systematic review on post-stroke care. European Journal of Health Economics, 2019, 20, 107-134.	2.8	300
3	Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study. Osteoporosis International, 2007, 18, 77-84.	3.1	272
4	The Epidemiology of Osteoporosis. Deutsches Ärztblatt International, 2013, 110, 52-7.	0.9	178
5	A systematic review and meta-analysis of the effects of clinical pathways on length of stay, hospital costs and patient outcomes. BMC Health Services Research, 2008, 8, 265.	2.2	121
6	STandardisierte BerichtsROutine fÅ¼r SekundÃrdaten Analysen (STROSA) â€“ ein konsentierter Berichtsstandard fÅ¼r Deutschland, Version 2. Gesundheitswesen, 2016, 78, e145-e160.	0.5	95
7	Pathways to care and psychological problems of general practice patients in a ?gate keeper? and an ?open access? health care system. Social Psychiatry and Psychiatric Epidemiology, 2003, 38, 690-697.	3.1	47
8	Early Termination of Antidepressant Drug Treatment. Journal of Clinical Psychopharmacology, 2000, 20, 523-530.	1.4	45
9	Benzodiazepine Substitution in Medical Practice. Pharmacopsychiatry, 1993, 26, 107-113.	3.3	31
10	Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Preference and Adherence, 2009, 3, 25-30.	1.8	29
11	The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 868-872.	0.6	28
12	Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. Journal of Human Hypertension, 2007, 21, 744-746.	2.2	26
13	Algorithms to identify COPD in health systems with and without access to ICD coding: a systematic review. BMC Health Services Research, 2019, 19, 737.	2.2	26
14	The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. Applied Health Economics and Health Policy, 2015, 13, 21-33.	2.1	25
15	Epidemiology and health care utilization of patients suffering from Huntingtonâ€™s disease in Germany: real world evidence based on German claims data. BMC Neurology, 2019, 19, 318.	1.8	24
16	Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. Pharmacoepidemiology and Drug Safety, 2007, 16, 854-858.	1.9	19
17	Do patients with lactose intolerance exhibit more frequent comorbidities than patients without lactose intolerance? An analysis of routine data from German medical practices. Annals of Gastroenterology, 2016, 29, 174-9.	0.6	18
18	Excess Health Care Costs of Obesity in Adults with Diabetes Mellitus: a Claims Data Analysis. Experimental and Clinical Endocrinology and Diabetes, 2010, 118, 496-504.	1.2	17

#	ARTICLE	IF	CITATIONS
19	Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. PLoS ONE, 2020, 15, e0231846.	2.5	16
20	Specialty Training and the Personal Use of Benzodiazepines by Physicians Affect their Proneness to Prescribe Tranquilizers. Pharmacopsychiatry, 1998, 31, 42-47.	3.3	12
21	A Germany-wide survey study on the patient journey of patients with hereditary angioedema. Orphanet Journal of Rare Diseases, 2020, 15, 221.	2.7	9
22	Economic Burden of Stroke: A Systematic Review on Post-Stroke Care. Value in Health, 2016, 19, A633.	0.3	8
23	The patient journey of patients with Fabry disease, Gaucher disease and Mucopolysaccharidosis type II: A German-wide telephone survey. PLoS ONE, 2020, 15, e0244279.	2.5	8
24	The impact of pharmaceuticals on the decline of cardiovascular mortality in Germany. Pharmacoepidemiology and Drug Safety, 2007, 16, 1167-1176.	1.9	7
25	Is there an unmet medical need for palliative care services in Germany? Incidence, prevalence, and 1-year all-cause mortality of palliative care sensitive conditions: real-world evidence based on German claims data. Zeitschrift Fur Gesundheitswissenschaften, 2022, 30, 711-720.	1.6	7
26	What Happens to Patients After the End of a Clinical Trial?. Pharmacopsychiatry, 1997, 30, 35-43.	3.3	3
27	Individual health services. GMS Health Technology Assessment, 2011, 7, Doc05.	2.2	3
28	Epidemiology and routine care treatment of patients with hip or knee osteoarthritis and chronic lower back pain: real-world evidence from Germany. Zeitschrift Fur Gesundheitswissenschaften, 2022, 30, 2855-2867.	1.6	3
29	The experience of conducting a Cochrane systematic review of the impact of clinical pathways on professional practice, patient outcomes, length of stay and hospital costs. International Journal of Care Pathways, 2009, 13, 62-66.	0.5	2
30	The Use Of Administrative Data To Determine Prevalence And Incidence Of Copd: A Systematic Review. Value in Health, 2016, 19, A368-A369.	0.3	2
31	Benzodiazepines in Medical Teaching. Pharmacopsychiatry, 1993, 26, 6-10.	3.3	1
32	PMD30 MODELLING OF PREVALENCE, COSTS AND OUTCOME OF ACID-RELATED DISORDERS USING CLAIMS DATA. Value in Health, 2003, 6, 802.	0.3	1
33	PMH31 PREDICTORS FOR REHOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA. Value in Health, 2006, 9, A319.	0.3	1
34	POB4 USING CLAIMS DATA TO UNDERSTAND THE COSTS OF DIFFERENT HEALTH STATES FOR PATIENTS WITH CARDIOMETABOLIC RISK. Value in Health, 2006, 9, A325.	0.3	1
35	The Impact of Generic Substitution on Health Outcomes and Costs: A Systematic Review. Value in Health, 2013, 16, A458.	0.3	1
36	Health technology assessment of utilization, practice and ethical issues of self-pay services in the German ambulatory health care setting. International Journal of Public Health, 2014, 59, 175-187.	2.3	1

#	ARTICLE	IF	CITATIONS
37	Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians. Preventive Medicine Reports, 2022, 28, 101861.	1.8	1
38	PRS2 PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN SICKNESS FUND POPULATION. Value in Health, 2005, 8, A212.	0.3	0
39	Low persistency with oral bisphosphonates in cancer patients. European Journal of Oncology Nursing, 2006, 10, 220-221.	2.1	0
40	PHP3 INNOVATIVE HEALTHTECHNOLOGIES IN THE "ANTI-AGING-MEDICINE" FIELD: RESULTS FROM A SYSTEMATIC HORIZON SCANNING. Value in Health, 2008, 11, A363.	0.3	0
41	PMS67 HEALTH GAINS FOREGONE DUE TO THE SUSTAINED DELAY OF ADEQUATE UTILIZATION OF EVIDENCE BASED TREATMENTS: THE CASE OF BISPHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS. Value in Health, 2008, 11, A558.	0.3	0
42	PMH54 INDICATION SPECTRUM OF SNRI APPLIED FOR THE TREATMENT OF DEPRESSION "A PHARMACOEPIDEMIOLOGICAL ANALYSIS OF CLAIMS DATA OF A GERMAN SICKNESS FUND. Value in Health, 2008, 11, A597.	0.3	0
43	PMH2 EVIDENCE FOR SSRI IN THE TREATMENT OF DEPRESSION: EARLY KNOWLEDGE GAIN "LATE CONSEQUENCES IN ROUTINE CARE?. Value in Health, 2009, 12, A350.	0.3	0
44	PHP153 Supporting Payers with Collaborative HTA Tools in Making Evidence-Based Decisions: The United States Experience and International Needs in Europe and Globally. Value in Health, 2012, 15, A316.	0.3	0
45	PMU9 - PALLIATIVE CARE IN GERMANY: AN EPIDEMIOLOGICAL STUDY BASED ON REAL WORLD DATA. Value in Health, 2018, 21, S309-S310.	0.3	0
46	Assessing Type and Impact of Biases Potentially Occurring when Analyzing Real World Evidence: The Case of Second Line Treatment for Ovarian Cancer. Value in Health, 2018, 21, S213.	0.3	0
47	Comparative Effectiveness Analysis Using Real World Evidence (RWE) and Applying a Causal Marginal Structural Model: the Case of Second-Line Treatment in Patients with Ovarian Cancer. Value in Health, 2018, 21, S18.	0.3	0
48	Jetzt einmalige Chance für Covid-19-Forschung nutzen. Monitor Versorgungsforschung, 2021, 14, 28-30.	0.0	0